Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
46.46
+4.81 (11.55%)
Nov 22, 2024, 4:00 PM EST - Market closed
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for PTGX stock have an average target of 53.57, with a low estimate of 43 and a high estimate of 65. The average target predicts an increase of 15.30% from the current stock price of 46.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PTGX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +7.62% | Nov 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +7.62% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +7.62% | Nov 11, 2024 |
| Wedbush | Wedbush | Buy Initiates $58 | Buy | Initiates | $58 | +24.84% | Nov 5, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +39.91% | Sep 24, 2024 |
Financial Forecast
Revenue This Year
298.16M
from 60.00M
Increased by 396.93%
Revenue Next Year
163.93M
from 298.16M
Decreased by -45.02%
EPS This Year
2.02
from -1.39
EPS Next Year
-1.45
from 2.02
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 398.0M | 619.5M | 424.2M | ||
| Avg | 298.2M | 163.9M | 197.2M | ||
| Low | 253.9M | n/a | 70.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 563.3% | 107.8% | 158.8% | ||
| Avg | 396.9% | -45.0% | 20.3% | ||
| Low | 323.2% | - | -57.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.18 | 1.83 | -1.10 | ||
| Avg | 2.02 | -1.45 | -2.01 | ||
| Low | 1.29 | -3.19 | -3.85 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | -9.5% | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.